148 related articles for article (PubMed ID: 28691859)
1. Preliminary studies of berberine and its semi-synthetic derivatives as a promising class of multi-target anti-parkinson agents.
Ribaudo G; Zanforlin E; Canton M; Bova S; Zagotto G
Nat Prod Res; 2018 Jun; 32(12):1395-1401. PubMed ID: 28691859
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, monoamine oxidase inhibitory activity and computational study of novel isoxazole derivatives as potential antiparkinson agents.
Agrawal N; Mishra P
Comput Biol Chem; 2019 Apr; 79():63-72. PubMed ID: 30731360
[TBL] [Abstract][Full Text] [Related]
3. Gamma-decanolactone: Preliminary evaluation as potential antiparkinsonian drug.
Pflüger P; Pereira P; Loza MI; Brea J; Viña D; Kumar A; Fontenla JA
Eur J Pharmacol; 2021 Sep; 906():174276. PubMed ID: 34174267
[TBL] [Abstract][Full Text] [Related]
4. Identification of Novel Phyto-chemicals from Ocimum basilicum for the Treatment of Parkinson's Disease using In Silico Approach.
Mubashir N; Fatima R; Naeem S
Curr Comput Aided Drug Des; 2020; 16(4):420-434. PubMed ID: 32883197
[TBL] [Abstract][Full Text] [Related]
5. Quinolinic Carboxylic Acid Derivatives as Potential Multi-target Compounds for Neurodegeneration: Monoamine Oxidase and Cholinesterase Inhibition.
Khan NA; Khan I; Abid SMA; Zaib S; Ibrar A; Andleeb H; Hameed S; Iqbal J
Med Chem; 2018; 14(1):74-85. PubMed ID: 28545383
[TBL] [Abstract][Full Text] [Related]
6. Docking Screens for Dual Inhibitors of Disparate Drug Targets for Parkinson's Disease.
Jaiteh M; Zeifman A; Saarinen M; Svenningsson P; Bréa J; Loza MI; Carlsson J
J Med Chem; 2018 Jun; 61(12):5269-5278. PubMed ID: 29792714
[TBL] [Abstract][Full Text] [Related]
7. DFT, ADME studies and evaluation of the binding with HSA and MAO-B inhibitory potential of protoberberine alkaloids from Guatteria friesiana: theoretical insights of promising candidates for the treatment of Parkinson's disease.
Tananta VL; Costa EV; Mary YS; Mary YS; S Al-Otaibi J; Costa RA
J Mol Model; 2023 Nov; 29(11):353. PubMed ID: 37907772
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of monoamine oxidase by indole and benzofuran derivatives.
Prins LH; Petzer JP; Malan SF
Eur J Med Chem; 2010 Oct; 45(10):4458-66. PubMed ID: 20674099
[TBL] [Abstract][Full Text] [Related]
9. Chemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold.
Cruz-Monteagudo M; Borges F; Cordeiro MNDS; Helguera AM; Tejera E; Paz-Y-Mino C; Sanchez-Rodriguez A; Perera-Sardina Y; Perez-Castillo Y
Curr Neuropharmacol; 2017 Nov; 15(8):1117-1135. PubMed ID: 28093976
[TBL] [Abstract][Full Text] [Related]
10. Performance of Force-Field- and Machine Learning-Based Scoring Functions in Ranking MAO-B Protein-Inhibitor Complexes in Relevance to Developing Parkinson's Therapeutics.
Murugan NA; Muvva C; Jeyarajpandian C; Jeyakanthan J; Subramanian V
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081086
[TBL] [Abstract][Full Text] [Related]
11. Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease.
Nam MH; Park M; Park H; Kim Y; Yoon S; Sawant VS; Choi JW; Park JH; Park KD; Min SJ; Lee CJ; Choo H
ACS Chem Neurosci; 2017 Jul; 8(7):1519-1529. PubMed ID: 28332824
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
13. Discovery, biological evaluation, and structure-activity and -selectivity relationships of 6'-substituted (E)-2-(benzofuran-3(2H)-ylidene)-N-methylacetamides, a novel class of potent and selective monoamine oxidase inhibitors.
Pisani L; Barletta M; Soto-Otero R; Nicolotti O; Mendez-Alvarez E; Catto M; Introcaso A; Stefanachi A; Cellamare S; Altomare C; Carotti A
J Med Chem; 2013 Mar; 56(6):2651-64. PubMed ID: 23437843
[TBL] [Abstract][Full Text] [Related]
14. Understanding the Molecular Determinant of Reversible Human Monoamine Oxidase B Inhibitors Containing 2H-Chromen-2-One Core: Structure-Based and Ligand-Based Derived Three-Dimensional Quantitative Structure-Activity Relationships Predictive Models.
Mladenović M; Patsilinakos A; Pirolli A; Sabatino M; Ragno R
J Chem Inf Model; 2017 Apr; 57(4):787-814. PubMed ID: 28291352
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents.
Carradori S; Ortuso F; Petzer A; Bagetta D; De Monte C; Secci D; De Vita D; Guglielmi P; Zengin G; Aktumsek A; Alcaro S; Petzer JP
Eur J Med Chem; 2018 Jan; 143():1543-1552. PubMed ID: 29126727
[TBL] [Abstract][Full Text] [Related]
16. The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
Van der Walt MM; Terre'Blanche G; Petzer A; Petzer JP
Bioorg Chem; 2015 Apr; 59():117-23. PubMed ID: 25746740
[TBL] [Abstract][Full Text] [Related]
17. 2-Heteroarylidene-1-indanone derivatives as inhibitors of monoamine oxidase.
Nel MS; Petzer A; Petzer JP; Legoabe LJ
Bioorg Chem; 2016 Dec; 69():20-28. PubMed ID: 27662218
[TBL] [Abstract][Full Text] [Related]
18. [Monoamine oxidase as a target for drug action].
Drozak J; Kozłowski M
Postepy Hig Med Dosw (Online); 2006; 60():498-515. PubMed ID: 17060892
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of monoamine oxidase by selected C6-substituted chromone derivatives.
Legoabe LJ; Petzer A; Petzer JP
Eur J Med Chem; 2012 Mar; 49():343-53. PubMed ID: 22309913
[TBL] [Abstract][Full Text] [Related]
20. Monoamine Oxidase B Inhibitors in Parkinson's Disease.
Dezsi L; Vecsei L
CNS Neurol Disord Drug Targets; 2017; 16(4):425-439. PubMed ID: 28124620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
